ALT is now overvalued and could go down -50%

Based on our analysis, Altimmune has received an overvalued rating of 1 out of 5 stars from Cashu, primarily due to several concerning financial metrics that fall short of industry standards. One significant indicator of financial health is the net profit margin, which stands at -20,762.21%. This metric reflects how much profit a company makes for every dollar of revenue. In Altimmune's case, an exceptionally negative net profit margin highlights severe operational inefficiencies compared to the sector average of -138.75%. This suggests that Altimmune is struggling to manage its costs effectively, raising concerns about its profitability potential. Another crucial ratio is the return on equity (ROE), which registers at -45.57%. ROE measures a company's ability to generate profit from shareholders' equity. Altimmune's negative ROE indicates that it is not only failing to generate profits but is also eroding shareholder value more than the sector average of -74.35%. This raises questions about the company's long-term viability and its capacity to provide returns to investors. Lastly, the return on assets (ROA) ratio is at -41.99%, which measures how efficiently a company uses its assets to generate earnings. Altimmune’s ROA is also below the sector average of -47.85%, suggesting that while it is performing better than some peers, it still struggles significantly in asset utilization. These financial ratios highlight fundamental weaknesses in Altimmune's business performance, contributing to its overvalued status in the market. This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.